Corticosteroid use in neurocysticercosis

Expert Review of Neurotherapeutics

Volumn 11, Issue 8, 2011, Pages 1175-1183

  Nash, Theodore E ^a   Mahanty, Siddhartha ^a   Garcia, Hector H ^b,c,d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c INSTITUTO NACIONAL DE CIENCIAS NEUROLÓGICAS   (Peru)

^d Instituto Peruano de Parasitologia Clinica y Experimental   (Peru)

Author keywords

central nervous system; corticosteroids; cysticercosis; neurocysticercosis; seizures; Taenia solium

Indexed keywords

ALBENDAZOLE; ALBENDAZOLE SULFOXIDE; ANTICONVULSIVE AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOHEXIMIDE; CYCLOOXYGENASE 2; DEXAMETHASONE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FOLIC ACID; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; PRAZIQUANTEL; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ASEPTIC NECROSIS; BRAIN CALCIFICATION; BRAIN EDEMA; CENTRAL NERVOUS SYSTEM; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HIP DISEASE; HUMAN; HYDROCEPHALUS; IMMUNE RESPONSE; INFLAMMATION; LIFE CYCLE; LOW DRUG DOSE; NEUROCYSTICERCOSIS; PATHOGENESIS; REVIEW; SEIZURE; SIDE EFFECT; TAENIA SOLIUM; TAENIASIS; TREATMENT DURATION; TREATMENT WITHDRAWAL; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; ANIMALS; ANTHELMINTICS; ANTI-INFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM; HUMANS; NEUROCYSTICERCOSIS; TAENIA SOLIUM;

EID: 79961044186     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.86     Document Type: Review

References (61)

1. Garcia HH, Del Brutto OH. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol. 4(10), 653-661 (2005). (Pubitemid 41317300)
2. Flisser A. Taeniasis and cysticercosis due to Taenia solium. Prog. Clin. Parasitol. 4, 77-116 (1994).
3. Mahanty S, Garcia HH. Cysticercosis and neurocysticercosis as pathogens affecting the nervous system. Prog. Neurobiol. 91(2), 172-184 (2010).
4. Lobato RD, Lamas E, Portillo JM et al. Hydrocephalus in cerebral cysticercosis. Pathogenic and therapeutic considerations. J. Neurosurg. 55(5), 786-793 (1981). (Pubitemid 12198491)
5. Bickerstaff ER, Cloake PCP, Hughes B, Smith WT. The racemose form of cerebral cysticercosis. Brain 75, 1-16 (1952).
6. Estanol B, Corona T, Abad P. A prognostic classification of cerebral cysticercosis: therapeutic implications. J. Neurol. Neurosurg. Psychiatry 49(10), 1131-1134 (1986). (Pubitemid 16028694)
7. Nash TE, Singh G, White AC et al. Treatment of neurocysticercosis: current status and future research needs. Neurology 67(7), 1120-1127 (2006). (Pubitemid 44563815)
8. Dumas JL, Vusy JM, Belin C. Parenchymal neurocysticercosis: follow up and staging by MRI. Neuroradiology 39, 12-16 (1997).
9. Garcia HH, Del Brutto OH. Imaging findings in neurocysticercosis. Acta Tropica 87, 71-78 (2003). (Pubitemid 36629485)
10. Nash TE, Del Brutto OH, Butman JA et al. Calcific neurocysticercosis and epileptogenesis. Neurology 62(11), 1934-1938 (2004). (Pubitemid 38738199)
11. Sheth TN, Pillon L, Keystone J, Kucharczyk W. Persistent MR contrast enhancement of calcified neurocysticercosis lesions. AJNR Am. J. Neuroradiol. 19(1), 79-82 (1998). (Pubitemid 30430587)
12. Ooi WW, Wijemanne S, Thomas CB, Quezado M, Brown CR, Nash TE. A calcified Taenia solium granuloma associated with recurrent perilesiona edema causing refractory seizures: histopathological features. Am. J. Trop. Med. Hyg. (2011) (In press).
13. Nash TE, Pretell EJ, Lescano AG et al. Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol. 7(12), 1099-1105 (2008).
14. Nash TE, Pretell J, Garcia HH. Calcified cysticerci provoke perilesional edema and seizures. Clin. Infect. Dis. 33(10), 1649-1653 (2001). (Pubitemid 33044528)
15. Henneberg R. [Parasites of the central nervous system]. In:Handbuch Der Neurologie. Lewandowsky M (Ed.).Verlag Von Julius Springer, Berlin, Germany, 643-712 (1912).
16. Fleury A, Escobar A, Fragoso G, Sciutto E, Larralde C. Clinical heterogeneity of human neurocysticercosis results from complex interactions among parasite, host and environmental factors. Trans. R. Soc. Trop. Med. Hygiene 104(4), 243-250 (2010).
17. De Melo CS, Vaz AJ, Nakamura PM, Da Silva MV, Machado Ade B. Human neurocysticercosis. IgE in cerebrospinal fluid. Arq. Neuropsiquiatr. 55(1), 8-11 (1997). (Pubitemid 127508724)
18. Bueno EC, dos Ramos Machado L, Livramento JA, Vaz AJ. Cellular immune response of patients with neurocysticercosis (inflammatory and non-inflammatory phases).Acta Trop. 91(2), 205-213 (2004). (Pubitemid 38952722)
19. Chavarria A, Alcocer-Varela J. Is damage in central nervous system due to inflammation? Autoimmun. Rev. 3(4), 251-260 (2004). (Pubitemid 38887620)
20. Alvarez JI, Rivera J, Teale JM. Differential release and phagocytosis of tegument glycoconjugates in neurocysticercosis: implications for immune evasion strategies. PLoS Negl. Trop. Dis. 2(4), e218 (2008).
21. Terrazas LI. The complex role of pro- and anti-inflammatory cytokines in cysticercosis: immunological lessons from experimental and natural hosts. Curr. Top. Med. Chem. 8(5), 383-392 (2008). (Pubitemid 351791016)
22. Cardona AE, Restrepo BI, Jaramillo JM, Teale JM. Development of an animal model for neurocysticercosis: immune response in the central nervous system is characterized by a predominance of g d T cells. J. Immunol. 162(2), 995-1002 (1999). (Pubitemid 29035426)
23. Cardona AE, Teale JM. g/d T cell-deficient mice exhibit reduced disease severity and decreased inflammatory response in the brain in murine neurocysticercosis. J. Immunol. 169(6), 3163-3171 (2002). (Pubitemid 35013162)
24. Alvarez JI, Teale JM. Breakdown of the blood brain barrier and blood-cerebrospinal fluid barrier is associated with differential leukocyte migration in distinct compartments of the CNS during the course of murine NCC. J. Neuroimmunol. 173(1-2), 45-55 (2006).
25. Alvarez JI, Colegial CH, Castano CA, Trujillo J, Teale JM, Restrepo BI. The human nervous tissue in proximity to granulomatous lesions induced by Taenia solium metacestodes displays an active response. J. Neuroimmunol. 127(1-2), 139-144 (2002). (Pubitemid 34603584)
26. Tuckermann JP, Kleiman A, McPherson KG, Reichardt HM. Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit. Rev. Clin. Lab. Sci. 42(1), 71-104 (2005). (Pubitemid 41656710)
27. Lowenberg M, Stahn C, Hommes DW, Buttgereit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 73(9-10), 1025-1029 (2008).
28. Baschant U, Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J. Steroid Biochem. Mol. Biol. 120(2-3), 69-75 (2010).
29. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. 228(2), 111-133 (2003). (Pubitemid 36187918)
30. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc. Natl Acad. Sci. USA 89(21), 9991-9995 (1992).
31. Pitzalis C, Pipitone N, Bajocchi G et al. Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: an additional mechanism for their anti-inflammatory and immunosuppressive effect. J. Immunology 158(10), 5007-5016 (1997). (Pubitemid 127483827)
32. Brewer JA, Kanagawa O, Sleckman BP, Muglia LJ. Thymocyte apoptosis induced by T cell activation is mediated by glucocorticoids in vivo. J. Immunol. 169(4), 1837-1843 (2002). (Pubitemid 34857645)
33. Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell. Mol. Life Sci. 63(1), 60-72 (2006). (Pubitemid 43100281)
34. Bhattacharyya S, Brown DE, Brewer JA, Vogt SK, Muglia LJ. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 109(10), 4313-4319 (2007). (Pubitemid 46743398)
35. Kitajima T, Ariizumi K, Bergstresser PR, Takashima A. A novel mechanism of glucocorticoid-induced immune suppression: the inhibiton of T cell-mediated terminal maturation of a murine dendritic cell line. J. Clin. Invest. 98(1), 142-147 (1996). (Pubitemid 26243830)
36. Cumberbatch M, Dearman RJ, Kimber I. Inhibition by dexamethasone of Langerhans cell migration: influence of epidermal cytokine signals. Immunopharmacology 41(3), 235-243 (1999). (Pubitemid 29243826)
37. Matyszak MK, Citterio S, Rescigno M, Ricciardi-Castagnoli P. Differential effects of corticosteroids during different stages of dendritic cell maturation. Eur. J. Immunol. 30(4), 1233-1242 (2000). (Pubitemid 30216241)
38. Kim KD, Choe YK, Choe IS, Lim JS. Inhibition of glucocorticoid-mediated, caspase-independent dendritic cell death by CD40 activation. J. Leukoc. Biol. 69(3), 426-434 (2001). (Pubitemid 32221447)
39. Reichardt HM, Tuckermann JP, Gottlicher M et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 20(24), 7168-7173 (2001). (Pubitemid 34062308)
40. De Bosscher K, Haegeman G. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol. Endocrinol. 23(3), 281-291 (2009).
41. White AC Jr. New developments in the management of neurocysticercosis. J. Infect. Dis. 199(9), 1261-1262 (2009).
42. Alvarez JI, Mishra BB, Gundra UM, Mishra PK, Teale JM. Mesocestoides corti intracranial infection as a murine model for neurocysticercosis. Parasitology 137(3), 359-372 (2010).
43. Spina-Franca A, Nobrega JP, Livramento JA, Machado LR. Administration of praziquantel in neurocysticercosis. Tropenmed. Parasitol. 33(1), 1-4. (1982). (Pubitemid 12130909)
44. Garcia HH, Pretell EJ, Gilman RH et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N. Engl. J. Med. 350(3), 249-258 (2004). (Pubitemid 38067637)
45. Mall RK, Agarwal A, Garg RK, Kar AM, Shukla R. Short course of prednisolone in Indian patients with solitary cysticercus granuloma and new-onset seizures. Epilepsia 44(11), 1397-1401 (2003). (Pubitemid 37385847)
46. Garg RK, Potluri N, Kar AM et al. Short course of prednisolone in patients with solitary cysticercus granuloma: a double blind placebo controlled study. J. Infect. 53(1), 65-69 (2006). (Pubitemid 43960437)
47. Kishore D, Misra S. Short course of oral prednisolone on disappearance of lesion and seizure recurrence in patients of solitary cysticercal granuloma with single small enhancing CT lesion: an open label randomized prospective study. J. Assoc. Physicians India 55, 419-424 (2007).
48. Prakash S, Garg RK, Kar AM et al. Intravenous methyl prednisolone in patients with solitary cysticercus granuloma: a random evaluation. Seizure 15(5), 328-332 (2006). (Pubitemid 43812245)
49. Singhi P, Singhi S. Neurocysticercosis in children. Indian J. Pediatr. 76(5), 537-545 (2009).
50. Carpio A, Kelvin EA, Bagiella E et al. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J. Neurol. Neurosurg. Psychiatry 79(9), 1050-1055 (2008).
51. Carpio A, Santillan F, Leon P, Flores C, Hauser WA. Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch. Intern. Med. 155(18), 1982-1988 (1995).
52. Takayanagui OM, Odashima NS. Clinical aspects of neurocysticercosis. Parasitol. Int. 55(Suppl.), S111-S115 (2006). (Pubitemid 43188938)
53. Marquez-Caraveo C, Gongora-Rivera F, Santos Zambrano J, Hernandez R, Soto-Hernandez JL. Pre-treatment with corticosteroids and a single cycle of high dose albendazole for subarachnoidal cysticercosis. J. Neurol. Neurosurg. Psychiatry 75(6), 938-939 (2004). (Pubitemid 38658531)
54. Sotelo J. Treatment of brain cysticercosis. Surg. Neurol. 48(2), 110-112 (1997). (Pubitemid 27329330)
55. Sotelo J, Jung H. Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clin. Pharmacokinet. 34(6), 503-515 (1998). (Pubitemid 28271899)
56. Agapejev S, Da Silva MD, Ueda AK. Severe forms of neurocysticercosis: treatment with albendazole. Arq. Neuropsiquiatr. 54(1), 82-93 (1996).
57. Poeschl P, Janzen A, Schuierer G, Winkler J, Bogdahn U, Steinbrecher A. Calcified neurocysticercosis lesions trigger symptomatic inflammation during antiparasitic therapy. AJNR Am. J. Neuroradiol. 27(3), 653-655 (2006). (Pubitemid 44897793)
58. Vazquez ML, Jung H, Sotelo J. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology 37(9), 1561-1562 (1987). (Pubitemid 17132348)
59. Jung H, Hurtado M, Medina MT, Sanchez M, Sotelo J. Dexamethasone increases plasma levels of albendazole. J. Neurol. 237(5), 279-280 (1990). (Pubitemid 20259983)
60. Takayanagui OM, Lanchote VL, Marques MP, Bonato PS. Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Ther. Drug Monit. 19(1), 51-55 (1997). (Pubitemid 28068995)
61. Mitre E, Talaat KR, Sperling MR, Nash TE. Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis. Clin. Infect. Dis. 44(4), 549-553 (2007). (Pubitemid 46233257)